Cerevance Inc.

Despite missing the primary endpoint of a Phase II trial testing solengepras (CVN424) in early, untreated Parkinson’s disease, Cerevance pointed to positive numerical trends on several key secondary e

The quarterly Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) reported biopharma start-ups raised $5.9bn in the first quarter of 2024 – more than the sector r

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an

Curie.Bio launched on 14 February with $520m to provide $5m-$7m in seed financing per start-up, plus access to in-house expertise and external research services, to help new biopharmas generate enough